methyl-(5-methyl-pyrimidin-4-yl)-amine | 52698-53-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: methyl-(5-methyl-pyrimidin-4-yl)-amine
• 英文别名: N,5-dimethylpyrimidin-4-amine
• CAS: 52698-53-0
• 化学式: C₆H₉N₃
• mdl: MFCD18820914
• 分子量: 123.158
• InChiKey: WLSQQGAREJHYCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] ETHYNYL DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS D'ÉTHYNYLE A TITRE DE MODULATEURS DU RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017009275A1

  公开（公告）日：2017-01-19

  The present invention relates to compounds of formula I wherein R1 is lower alkyl; R2 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; n is 0, 1 or 2; V/U are independently from each other O or CH2, wherein V and U cannot be simultaneously O; L is a five or six membered heteroaryl group, selected from or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.

  本发明涉及式I的化合物，其中R1为较低的烷基；R2为苯基或吡啶基，吡啶基中的N原子可能位于不同位置；n为0、1或2；V/U分别为O或CH2，其中V和U不能同时为O；L为选自五元或六元杂环芳基团的杂环芳基团，选择自药用盐或酸加盐，对于外消旋混合物，或对应的对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗帕金森病、焦虑症、呕吐、强迫症、自闭症、神经保护、癌症、抑郁症和2型糖尿病。
• SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：Caruso Michele

  公开号：US20100216808A1

  公开（公告）日：2010-08-26

  Pyrazolo-quinazoline derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明揭示了式（I）中所定义的吡唑并喹唑啉衍生物及其药学上可接受的盐，以及它们的制备方法和包含它们的制药组合物；本发明中的化合物在治疗与蛋白激酶活性失调相关的疾病，如癌症中可能有用。
• Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US10766880B2

  公开（公告）日：2020-09-08

  Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  取代的 1,2,3-三唑作为 NR2B 受体配体。此类化合物可用于 NR2B 受体调节以及治疗由 NR2B 受体活性介导的疾病状态、紊乱和病症的药物组合物和方法中。
• SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20180334451A1

  公开（公告）日：2018-11-22

  Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.